Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 13 Issue 4, November 2019

Volume 13 Issue 4

In this issue...

• The art of closing a biopharma deal

• Targeting common viral denominators to fight flu

Cover image: Conceptual image of the influenza virus causing flu. Stocktrek Images, Inc. / Alamy Stock Photo.


  • News Feature |

    Even for the most seasoned dealmakers, successful deals require coordination, planning and collaboration throughout the process. This article explores the people and stages required to close a successful licensing and collaboration deal from the perspective of dealmakers at Eli Lilly.

    • Jennifer M. A. Laird
    • Katie Hewitt


  • Advertisement Feature |

    Aptorum is developing novel drugs that tackle bacteria and viruses. Acting as the commercialization platform in partnership with major academic and research institutions, the company has in-licensed a number of infectious-disease-targeted compounds and methods from Hong Kong academic institutions and through the company’s research and development team continue to advance them toward clinical development. Aptorum is now looking to develop further projects with collaborators globally

    • Aptorum Group Limited
  • Advertisement Feature |

    Recce Pharmaceuticals is commercializing a novel synthetic broad-spectrum antibiotic designed to overcome antimicrobial resistance. Its lead compound, RECCE 327, is one of the first entirely new classes of antibiotics to be developed in more than 30 years.

    • Recce Pharmaceuticals
  • Advertisement Feature |

    Atriva Therapeutics is developing a unique portfolio of broadly active and efficacious antiviral drugs based on MEK inhibitors, including its lead candidate ATR-002, which may revolutionize the treatment of influenza and other severe respiratory viral infections.

    • Atriva Therapeutics
  • Advertisement Feature |

    Building on its history of successful collaborations, Sanofi Pasteur, the vaccines global business unit of Sanofi, is seeking partners with a common drive for excellence and pursuit of innovation.

    • Sanofi Pasteur
  • Advertisement Feature |

    ImmuneMed is developing both its phase 2-ready antiviral drug candidate hzVSF to treat viral diseases including chronic hepatitis B virus (HBV) infection and a line of rapid diagnostic kits to test for acute febrile infectious diseases.

    • ImmuneMed, Inc.
  • Advertisement Feature |

    Rezolute, Inc. is developing transformative therapies for rare and metabolic diseases. The company’s lead phase 2 candidate RZ358, has received orphan designation in both the US and Europe and is now on the path to potentially becoming a universal treatment for the disorder

    • Rezolute, Inc.
  • Advertisement Feature |

    With its dynamic end-to-end in-house capabilities, Henlius has developed a unique pipeline of cancer and autoimmune drugs, including HLX01, a biosimilar version of MabThera. The company is now exploring the creation of further biosimilars and immuno-oncology combination therapies

    • Henlius Biotech
  • Advertisement Feature |

    D&D Pharmatech funds the development of innovative therapeutic and diagnostic solutions to address critical unmet healthcare needs. D&D subsidiary Theraly Fibrosis is developin a novel treatment for chronic pancreatitis and other fibrosis, recently granted an orphan drug designation from the US FDA.

    • D&D PharmaTech
  • Advertisement Feature |

    Genome & Company is developing a microbiome-based add-on therapy for programmed cell death 1/programmed cell death 1 ligand 1 inhibitors. It is also developing novel targeted immune checkpoint inhibitors, and believes these two approaches could be combined for personalized therapy.

    • Genome & Company


Quick links